Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells

25 Feb 2019

Abstract excerpt

Chimeric antigen receptor (CAR) engineering of T cells allows one to specifically target tumor cells via cell surface antigens. A candidate target in Ewing sarcoma is the ganglioside G D2 , but heterogeneic expression limits its value. Here we report that pharmacological inhibition of Enhancer of Zeste Homolog 2 (EZH2) at doses reducing H3K27 trimethylation, but not cell viability, selectively and reversibly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Renal and related cancers
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30879952
DOI: 10.1016/j.ymthe.2019.02.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T CellsPMID 30879952Read ↗

Model-dependent GD2 upregulation in Ewing sarcoma with the EZH2 inhibitor tazemetostat: Prerequisites for combination with GD2-specific CAR T cellsSemantic proximity Read ↗

EZH2 inhibition enhances NK cell-mediated cytotoxicity and potentiates anti-GD2 immunotherapy in neuroblastomaSemantic proximity Read ↗

EZH2: an epigenetic gatekeeper promoting lymphomagenesis.Semantic proximity Read ↗

Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemiaSemantic proximity Read ↗

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationSemantic proximity Read ↗

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.Semantic proximity Read ↗

EZH2 expands breast stem cells through activation of NOTCH1 signalingSemantic proximity Read ↗

EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.Semantic proximity Read ↗

Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation<strong> </strong>Semantic proximity Read ↗

High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.Semantic proximity Read ↗

Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.Semantic proximity Read ↗

EZH2 knockout in oral cavity basal epithelia causes more invasive squamous cell carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.